Published results showed bone marrow-derived mesenchymal stem cell implantation may be equally effective and safe as autologous chondrocyte implantation for the treatment of full-thickness cartilage defects of the knee.
Researchers assessed 72 patients who underwent either intra-articular autologous bone marrow-derived mesenchymal stem cell implantation or autologous chondrocyte implantation for treatment of full-thickness cartilage defects of the knee with SF-36 scores, the IKDC knee evaluation form, the Lysholm Knee Score and the Tegner Activity Scale. Researchers also obtained information on any additional surgical procedures and safety data, including infection and tumor formation.
After cartilage repair surgery, results showed improvements in all patient-reported outcome scores except for the mental component summary of the SF-36. Researchers found no significant difference between the bone marrow-derived mesenchymal stem cell group and the autologous chondrocyte implantation group in any of the patient-reported outcomes at any time point. Subsequent surgical procedures occurred in six patients in the autologous chondrocyte implantation group and in five patients in the bone marrow-derived mesenchymal stem cell group, according to results. Within the follow-up period, researchers noted no deep infections or tumors within either group.
“The ease of culture expansion as compared with chondrocytes may prove to be a decisive advantage in the older patient cohort as the age indications for these regenerative procedures continues to expand,” the authors wrote. “Moreover, [bone marrow-derived mesenchymal stem cells] BMSCs are relatively easy to isolate, with the advantage of avoiding a second surgical procedure and the associated donor site morbidity.” – by Casey Tingle
Disclosures: The authors report no relevant financial disclosures.